{"ticker": {"uuid": "e3b2f9fc-121b-4a85-adfb-3528d4cc30f7", "symbol": "TPST", "name": "Tempest Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com", "summary": "Tempest Therapeutics announced plans to initiate a clinical trial for its lead in vivo CAR-T candidate, TPST-4003, for nervous system autoimmune diseases, including myasthenia gravis and multiple sclerosis. The trial is expected to enroll around 10 patients, with the first dosing", "url": "https://m.za.investing.com/news/stock-market-news/tempest-plans-trial-of-in-vivo-cart-candidate-for-autoimmune-diseases-93CH-4369842?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T19:10:39", "published_display": "15 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNd3I3WXRZVlVIS1JPQmxEeGYtM1hlLTBlN1QyRGNGQmVtT01BSG92d2xISUVISjlEV0hXT3dBdTV3ZXpXMW9sQTQtRlRlNG9lZTcwdVdpV0RZX3AxQ0NmMHhybTFaNkFBc05IcXlhR1BlUzhialpVcHdFUzJGT29rYzJnSldKWktDYnhGVU9CZUJ3Z3lQbHo2QzhOSEYxV2FlMkJyR0FPVWgzdnRTbXFMYVF1NkRXd0RlTEN3bC0xZDYtcy01VGZWWUhSa1J0UUxEMVludTlrTkR0WGdEelZ0bjJqU1M3Y2VtcHk4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T11:13:00+00:00", "published_display": "15 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Unveils Next-Generation In Vivo CAR-T Pipeline", "summary": "Tempest Therapeutics has announced its next-generation in vivo CAR-T pipeline, with the lead candidate TPST-4003 targeting nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The company plans to initiate a clinical trial for TPST-4003 in the fourth ", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/Tempest-Unveils-Next-Generation-In-Vivo-CAR-T-Pipeline-with-First-Clinical-Study-Planned-for-the-Fourth-Quarter-of-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:10:39", "published_display": "15 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest's planned CAR-T study targets myasthenia gravis and MS", "summary": "Tempest Therapeutics announced plans to advance its lead in vivo CAR-T candidate, TPST-4003, into a 10-patient investigator-initiated clinical trial targeting nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The study, anticipated to start dosing ", "url": "https://www.stocktitan.net/news/TPST/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-97ghsim5w5yg.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:59:42", "published_display": "15 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026", "summary": "Tempest Therapeutics announced details of its next-generation in vivo CAR-T platform, with their lead candidate TPST-4003 advancing into a clinical trial for nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The company plans to dose the first pati", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-planned-for-the-fourth-quarter-of-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T10:59:42", "published_display": "15 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants", "summary": "Tempest Therapeutics (NASDAQ: TPST) has registered 2,426,897 shares of its common stock for resale, comprising shares issuable upon the exercise of newly issued warrants and placement agent warrants. The company will not receive proceeds from the direct resale of these shares by ", "url": "https://www.stocktitan.net/sec-filings/TPST/424b3-tempest-therapeutics-inc-prospectus-filed-pursuant-to-rule-424--df77ab77984a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:36", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Tempest Therapeutics, Inc. SEC Filing", "summary": "This article reports on an SEC filing by Tempest Therapeutics, Inc. (TPST), specifically an \"EFFECT\" filing which is a Notice of Effectiveness for an S-3 Shelf Registration. The filing was accepted by the SEC on July 8, 2026, and became effective on July 7, 2026. The report also ", "url": "https://www.stocktitan.net/sec-filings/TPST/effect-tempest-therapeutics-inc-sec-filing-66dc73ad19eb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:09:36", "published_display": "08 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter", "summary": "Tempest Therapeutics is seeking shareholder approval to amend its certificate of incorporation, aiming to replace existing supermajority voting requirements with majority-of-outstanding standards and permit stockholder action by written consent. The Board unanimously recommends a", "url": "https://www.stocktitan.net/sec-filings/TPST/pre-14a-tempest-therapeutics-inc-preliminary-proxy-statement-40c3de5ad0b5.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:44:23", "published_display": "07 Jul 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tempest Therapeutics, Inc. \u2013 NASDAQ:TPST", "summary": "The article focuses on the enterprise value to revenue forward metric for Tempest Therapeutics, Inc. (NASDAQ: TPST). It appears to be a financial data point presented within a TradingView context, potentially indicating an analysis or overview of the company's valuation. However,", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:10:50", "published_display": "04 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Names Nicholas Maestas CFO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-names-nicholas-maestas-125504442.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:55:04+00:00", "published_display": "29 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TPST Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Tempest Therapeutics, Inc. (TPST), including analyst price targets and future predictions. It details the company's current stock performance, market capitalization, earnings, and revenue, alongside responses to frequently asked questions abou", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T05:09:10", "published_display": "27 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Registers 2.43 Million Shares for Resale", "summary": "Tempest Therapeutics has registered 2.43 million shares for resale, as detailed in a recent SEC filing. This move allows existing shareholders, likely including certain investors or employees, to sell their shares on the open market. The registration does not indicate a new issua", "url": "https://www.moomoo.com/news/post/72126797/tempest-therapeutics-registers-2-43-million-shares-for-resale?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-27T00:09:10", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TPST: Selling Stockholders Plan to Offer 2.43 Million Shares", "summary": "Certain stockholders of Tempest Therapeutics Inc (TPST) plan to sell 2.43 million shares of common stock. The company itself will not participate in the sale or benefit from the proceeds. TPST, a small-cap biotechnology company with a market cap of $15.99 million, has a low GF Sc", "url": "https://www.gurufocus.com/news/8934705/tpst-selling-stockholders-plan-to-offer-243-million-shares", "source_name": "GuruFocus", "published_at": "2026-06-26T20:40:39", "published_display": "26 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants", "summary": "Tempest Therapeutics (NASDAQ: TPST) has registered up to 2.43 million shares of common stock for resale by selling stockholders, stemming from new and placement agent warrants. The company will not receive proceeds from these resales, but could gain approximately $4.23 million if", "url": "https://www.stocktitan.net/sec-filings/TPST/s-3-tempest-therapeutics-inc-shelf-registration-statement-cd969c4f007b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T19:40:39", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Tempest Therapeutics, Inc. \u2013 NASDAQ:TPST", "summary": "This page provides financial data, primarily the \"Price to earnings forward\" value, for Tempest Therapeutics, Inc. (NASDAQ: TPST). It indicates that the company's market is currently closed with no trades. The content is essentially a snapshot of a financial data point from Tradi", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:39:31", "published_display": "26 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tempest Therapeutics, Inc. \u2013 NASDAQ:TPST", "summary": "This page displays the \"Price to sales forward\" metric for Tempest Therapeutics, Inc. (NASDAQ: TPST) on TradingView. The content is primarily navigation and boilerplate information from the TradingView platform, with no specific financial data or analysis for TPST provided on thi", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:49", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tempest Therapeutics, Inc. \u2013 LS:A41556", "summary": "This article provides the \"Price to sales forward\" value for Tempest Therapeutics, Inc. (A41556) on TradingView. It indicates that the market is closed and no trades have occurred for this specific period, presenting the financial data as \"No trades.\" The brief content focuses so", "url": "https://www.tradingview.com/symbols/LS-A41556/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:39:31", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST)", "summary": "This article provides an overview of Tempest Therapeutics, Inc. (NASDAQ:TPST) stock performance, financial actuals, and future estimates. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report. The piece also", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:49", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TPST PE Ratio & Valuation, Is TPST Overvalued", "summary": "This article analyzes the valuation of Tempest Therapeutics Inc (TPST), stating that it is currently in the \"Fair zone\" based on its forward P/S ratio compared to its five-year average. It details various financial metrics such as P/B ratio and Free Cash Flow yield, noting signif", "url": "https://intellectia.ai/en/stock/TPST/valuation", "source_name": "Intellectia AI", "published_at": "2026-06-24T12:39:25", "published_display": "24 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Tempest Therapeutics Inc For: 23 June By Investing.com", "summary": "This article reports on the filing of a Form 8K by Tempest Therapeutics Inc. on June 23, 2026. The brief notice from Investing.com indicates this financial filing is available for public consumption. It is a standard reporting for a company, signifying a significant event worthy ", "url": "https://ng.investing.com/news/stock-market-news/form-8k-tempest-therapeutics-inc-for-23-june-93CH-2569463", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T03:41:07", "published_display": "24 Jun 2026 03:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tempest Therapeutics Inc For: 23 June By Investing.com", "summary": "The article reports on a Form 4 filing for Tempest Therapeutics Inc. on June 23, 2026, as published by Investing.com. It is a brief news item indicating a regulatory disclosure for the company. The specific details of the Form 4 filing are not included in this snippet.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tempest-therapeutics-inc-for-23-june-93CH-2571002", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T22:10:00", "published_display": "23 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants", "summary": "An entity linked to Tempest Therapeutics CEO, Factor Bioscience Inc., acquired 231,482 shares of common stock and warrants to purchase an additional 462,964 shares at a combined price of $2.16 per share plus a warrant. The CEO, Matthew Angel, controls Factor Bioscience and thus i", "url": "https://www.stocktitan.net/sec-filings/TPST/form-4-tempest-therapeutics-inc-insider-trading-activity-67904dbd08cd.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:25", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (Nasdaq:TPST) - Stock Analysis", "summary": "Tempest Therapeutics (TPST) is a clinical-stage biotechnology company focused on developing therapies for cancer, with a market capitalization of US$18.6 million. The company faces significant risks including shareholder dilution, negative earnings forecasts, low revenue, and Nas", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tpst/tempest-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-23T16:10:44", "published_display": "23 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) holders approve warrant share issuances", "summary": "Tempest Therapeutics (NASDAQ: TPST) stockholders approved two proposals at their 2026 Special Meeting, authorizing the potential issuance of common stock related to previously issued warrants. This includes shares for Series A, Series B, and Common Warrants, formalizing prior fin", "url": "https://www.stocktitan.net/sec-filings/TPST/8-k-tempest-therapeutics-inc-reports-material-event-882932a13584.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:10:39", "published_display": "23 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares", "summary": "Tempest Therapeutics shareholders have approved the issuance of up to 4.2 million common shares related to outstanding warrants, following a special meeting. The biotech company, trading near its 52-week low, secured these approvals under Nasdaq Rule 5635 due to thresholds on out", "url": "https://m.investing.com/news/sec-filings/tempest-therapeutics-shareholders-approve-issuance-of-up-to-42-million-shares-93CH-4755001?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T10:10:39", "published_display": "23 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics, Inc. 8-K Filing \u2013 Special Meeting Results, Common Stock Issuance Approved, Company Details (June 2026) \u2013 Minichart", "summary": "Tempest Therapeutics, Inc. announced the results of its 2026 Special Meeting, where shareholders approved the issuance of over 4 million new common shares under Nasdaq Rule 5635. These approvals for Series A and B warrants, and inducement offer warrants, enable the company to rai", "url": "https://www.minichart.com.sg/2026/06/23/tempest-therapeutics-inc-8-k-filing-special-meeting-results-common-stock-issuance-approved-company-details-june-2026/", "source_name": "Minichart", "published_at": "2026-06-23T10:10:39", "published_display": "23 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Tempest Therapeutics Inc (TPST), outlining major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over recent quarters, and recent shareholder activity with specific change", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tpst/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T16:10:52", "published_display": "18 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Inc (TPST) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Tempest Therapeutics Inc (TPST). It details the shares held by various institutional shareholders, including Angel (Matthew), Lotus Capital Limited, and Versant Ventures, along with changes in their ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tpst/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T14:09:30", "published_display": "18 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Inc (TPST) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Tempest Therapeutics Inc (TPST). It states that no dividends have been distributed over the past five years and lists several merger-related stock splits with their corresponding dates and ratios. The company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tpst/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:05", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Tempest Therapeutics (TPST) receives 25,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQQUQ0M1Ztc1Z6ODJlTC1iY0Jhc1VJSE1GYV8tUXpEYU82RXF5dXR3UDBpWVZhNGoxbFY2ekF1XzJWT01panZLRDVTcWZReEtIazdhbXAtTVZZNWtGMXEwV0xtSTZSdkxvZWZKUzIyS3BMMXE1RkxsMnhoNjdhUXZoRGlRSy14VXJEeWJiWDJXQmxrQUl1aS1SQUl6QzAtU1ZrSC1sandNbVZ2RmFncHlaUFBMdGp4Q0tFdmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 3] Tempest Therapeutics, Inc. Initial Statement of Beneficial Ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOdzlyTXBUSkY0LWJQVnRqdlh2M2d4SUNxZ2o1czU2N19BSjBSOVBqRFhtbkw5UVkwQWt0NjFaOE9JdnFyV09QSzZmd2F3RnR5cmtZbkZmVGVZczlibmhiemdpaTZ3OTB0LXpfaVcxYlBWRjN6UzQ0dW10dXpINWt6M1NxcjNQeFMtVXpFVTg3VWNDVHZyb2Y5b3ZUVkxRYXBKd05jVTBNcEtlbTNNeEthMU5xeGtPc0dOVE56TWhONkM2UEhMcG9oSFMxTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics CFO Nicholas Maestas Resigns", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-therapeutics-cfo-nicholas-maestas-100531808.html", "source_name": "MT Newswires", "published_at": "2026-06-05T10:05:31+00:00", "published_display": "05 Jun 2026 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-therapeutics-appoints-drake-richey-203700033.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T20:37:00+00:00", "published_display": "04 Jun 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest building CAR-T cancer drugs adds two seasoned directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWHJldjVSWjVFcnQwSXAzN2lnOEpYQWFCb095WmpCSWZtSTNxNzl1Z0loTGNONzhvWGtoTFBCeUZ3MGlYTXVEb0hQVy1oTG0yUXhEODg0SzBWWDdVcU8xa2J5anZHeXhtWmVCcU9QOEd1aTRSUEtMcE1Fa1RfdnB0Wk9KQ05hR05aVVFmT2w5Tl9sVFBiQ3l6XzRfQ1paRU1sN2FJRkwybmNTbHdfTC1HZG1UWFRaLU1UODBWMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOeXZ2NEpMME5rV0NDcE5lR0xadjI3NXdrak93M3FhZmpydTdfRnd4TUVpVWViN0xpMGc5WjlGZ2lCYThmMVZVVk1oNlVEQWF4a3JGaGI4dzQwSWVyaVhQVWg1Yk1FUDUwU05VamxaeEF5NUdVS1Z0cjgyVkFEdzdseVNITnZpa1VnM0VqTm1hOTlwNGZTRTNWODdhX2g2SG5mUDg1M01GdGVaTFF1OXVDby11cGpQLXcxaC1aWUJFLUhnLW4zVHBWUUg1VHlGbXljN2JfdGRoTE0zclFZV0NBU3lLNzBpYjctbW82ZXlVZkd5ZEhjQk1TUw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer-focused Tempest pursues $2M upfront, $4M potential in warrant deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNM1RxX0trSEh0WHR2ZlloQzNaaUw5Um9JSWpDU25QRkdMSHhJc2NXVU9EWWd4ZWpsdzFzSXVoa0VrZEdjTnFXVGZmYUoybGJZRjlDY0xuYk5wSjFCT2RXNWtrbWRLUXFQM3F4ZzFlOGZ4SG1MYVVLSUdmekpZQ1RXaVRLVjV3dXlfcUVEbnJZQmZQSVBfRXRESEpJZGlOVTRXNHZXT0JVa3R6eVhXbG5SckhMX2xVN3Rrb2xKRXY4cw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tempest Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNeDkzd0k0NGY0c1V0bmxPSFBHbmhzOXJBOEE5YkJOY29IWk5ldFBUMGRjQmlHSV8xRHBMaGN3ZklnUlFVZEJPZzV0dENEVlY4WkNDNmpQSHd6UkpEVlRBSlBDRENPc1lqcnQteFVDOUVGdzVERER1dTE2bG1KeVRZUkl2aDVmSlJKMmItMkl3Y1REZHRiemh3Tm15U1BscVV1Uk5fV1FyZ1BhUjBPdTlZNGttdEdKLWFjR1dDaVVnbmNmWERYRWZjV05teWFMM1I3RXBQS19WQzdNRm95ZGlXdGl4NTc2NVJV?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tempest Presents Clinical Update at ISCT 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-presents-clinical-isct-2026-110000573.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:00:00+00:00", "published_display": "06 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-advance-dual-targeting-car-120000162.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T12:00:00+00:00", "published_display": "29 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxOYUM5TFJjVHBocEJKYTJLejJHZUtOX0ZrY0U1Q2xsbGpfcllUMlhmZnV3dlhvak92X0lNbGdEcGRFUnVNc3Q4R3Z6YkdUZjJQb1pQRnlpZXBUMFFaRjhyS1BEbzh5LVV5N1ZSWXR5dkdqVUxDZ0F6Y2hoaDAzMl9wYzlJdGtvTVo0X3Q1VGpRZEhaU010c3RGTTF5Z080bVROdWJDLTVWaE02SUJsRC02TFcyN2wyY2NXbl90UWZZU09nWld6RDIwY3NELXFQTWlKTEhVbms2VUtIeGxLYVNSdWxBOUtncmRjZzlqZG1wZ1VDTkFL?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After 6 of 6 complete responses, Tempest moves toward pivotal CAR-T study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQb0k3Y0t5WWhwR0ZVcjFyZWwzNlY1T3psdTFuSXU4UTJab2JLN21HOGdQY2ViVS1yZ3pwRFdZV1BsUDE5MHdIbjRhdmpSWXNYRmM4elAtYjE5WndCQ3k5NGh5YW4xS2ptTHc1OXNMQkNxSHR0T0xFRXJBa2ZKdWFTWUtVSXZMZkI0eWNkY3RhWllybWpSeHljMDVOb0lzdExMVXBUM1NjTVJpeWRTSUlTaTRITzJiX21saTB3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should I buy Tempest Therapeutics (TPST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9haXVWS3QtbnpQb29kMGZHWjNxSF9QYjdfVzkxaGtqaXRfcnNEZFJJSXRJckRwX05rWmlfbGdJbWRrdlhWRE52WkttUUozaS1oWWlNNGF4MEo0SGhVVU1jeG1qVzVYbUNFcm9vSg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tempest Therapeutics Announces Up To $6 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPR1g0Ymc1XzB4bWNSbzJfcTVUZzBNQjcyemFQZVkxcUxWQnZiZGtxTnJhNGd5QlcwRzBYR3JUV0VEbDJCSW9RaXZGdjZReGpCVW1TX1BYV2w4MjFXazl0eHFkOFRFUkwxRFNoUDE2UFdISU1xdWg2RXE2Y1J5dmwzTl9DaHNJN0pJeFZIa0l1UWVFQmxSTjI4SThiUTZST0lyU2tMaDFLVDRZS2ZRb0Nfa3pFNHRQSnpkTDJXSVQ5TDZ5RF9CX19fQ0drTHdCOWw4Unc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOM2JOY1BUTDR5X2p5ckZScTQ5UHVEWGt4RkhBZE5RWm5sUERLdEJYX0pmT1ltZ1B5Vy1adWxhVzQ5SGxiUUtTNm90Q0gwRVpVdndmdGpXX3lUZDhsWHRJb3pRTXhNNmc2VXlNRUR0RHBoa1ExQW85WnVSOTEyWUtvbmZnenVoZFNHVkdSRXVDQ2UtTHZsaGwwTkF0VV9kMWFVV0JtcGxWSmNWOWtjY014Q2l5VUJHV1cwT1M4akkxTFE4M2xIcFU2bTN4dEExWDY3X2hnbEZZeE1zcjdaazBFR0lIYzgtOWtsTHRrVUNheVpic2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics stock plunges after all-stock acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNDhPN25jU0h1WnVtLS05T3pZN1ZPNnlwNVpJWUtKTGxyd2p6ejZiN3JHVGxHVGIzVXZwblN2UXFfZTZpaVhUWEZpUUtKLUNqNWdBYVNvU252V0RxRWVEMVctME5xaGNpUGY1aFNLSTFLT1ZZQ2ZwbHA4MUdwb0dhU2pQT253M1RIUTdWVC1wRjQ3U0F0SG1KRGJtaG0xQ09meGdkZ0pOOWVEekpaQ3gzTENrVW1PcENjUVJfQUw2OGM?oc=5", "source_name": "Investing.com", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (TPST) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9fdXBYdkRwc213LXQ5SmViSC1DM0pDck1CMWtDczNYRWNFSVZkZkk1MG5wNEFsdzhwSk5HbW52cnUteW05akxUNmowcWhFeUFiUlFV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:35:29+00:00", "published_display": "24 Apr 2025 17:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (TPST) Stock Price, News & Analysis $TPST", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5hQktWYk1PYTQ2aXVJdDhBenY0MXhNaDlBLWcwa2VsOHlWdnRaMzFMLVRPMzU2b2NnbW9GcjNZQXk0dURTQzhZNkpyRFFtVWVrMWxLWHRJS1dkdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-29T14:38:08+00:00", "published_display": "29 Jun 2021 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com", "summary": "Tempest Therapeutics announced plans to initiate a clinical trial for its lead in vivo CAR-T candidate, TPST-4003, for nervous system autoimmune diseases, including myasthenia gravis and multiple sclerosis. The trial is expected to enroll around 10 patients, with the first dosing", "url": "https://m.za.investing.com/news/stock-market-news/tempest-plans-trial-of-in-vivo-cart-candidate-for-autoimmune-diseases-93CH-4369842?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T19:10:39", "published_display": "15 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNd3I3WXRZVlVIS1JPQmxEeGYtM1hlLTBlN1QyRGNGQmVtT01BSG92d2xISUVISjlEV0hXT3dBdTV3ZXpXMW9sQTQtRlRlNG9lZTcwdVdpV0RZX3AxQ0NmMHhybTFaNkFBc05IcXlhR1BlUzhialpVcHdFUzJGT29rYzJnSldKWktDYnhGVU9CZUJ3Z3lQbHo2QzhOSEYxV2FlMkJyR0FPVWgzdnRTbXFMYVF1NkRXd0RlTEN3bC0xZDYtcy01VGZWWUhSa1J0UUxEMVludTlrTkR0WGdEelZ0bjJqU1M3Y2VtcHk4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T11:13:00+00:00", "published_display": "15 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Unveils Next-Generation In Vivo CAR-T Pipeline", "summary": "Tempest Therapeutics has announced its next-generation in vivo CAR-T pipeline, with the lead candidate TPST-4003 targeting nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The company plans to initiate a clinical trial for TPST-4003 in the fourth ", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/Tempest-Unveils-Next-Generation-In-Vivo-CAR-T-Pipeline-with-First-Clinical-Study-Planned-for-the-Fourth-Quarter-of-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:10:39", "published_display": "15 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest's planned CAR-T study targets myasthenia gravis and MS", "summary": "Tempest Therapeutics announced plans to advance its lead in vivo CAR-T candidate, TPST-4003, into a 10-patient investigator-initiated clinical trial targeting nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The study, anticipated to start dosing ", "url": "https://www.stocktitan.net/news/TPST/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-97ghsim5w5yg.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:59:42", "published_display": "15 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026", "summary": "Tempest Therapeutics announced details of its next-generation in vivo CAR-T platform, with their lead candidate TPST-4003 advancing into a clinical trial for nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis. The company plans to dose the first pati", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-planned-for-the-fourth-quarter-of-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T10:59:42", "published_display": "15 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants", "summary": "Tempest Therapeutics (NASDAQ: TPST) has registered 2,426,897 shares of its common stock for resale, comprising shares issuable upon the exercise of newly issued warrants and placement agent warrants. The company will not receive proceeds from the direct resale of these shares by ", "url": "https://www.stocktitan.net/sec-filings/TPST/424b3-tempest-therapeutics-inc-prospectus-filed-pursuant-to-rule-424--df77ab77984a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:09:36", "published_display": "08 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Tempest Therapeutics, Inc. SEC Filing", "summary": "This article reports on an SEC filing by Tempest Therapeutics, Inc. (TPST), specifically an \"EFFECT\" filing which is a Notice of Effectiveness for an S-3 Shelf Registration. The filing was accepted by the SEC on July 8, 2026, and became effective on July 7, 2026. The report also ", "url": "https://www.stocktitan.net/sec-filings/TPST/effect-tempest-therapeutics-inc-sec-filing-66dc73ad19eb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:09:36", "published_display": "08 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter", "summary": "Tempest Therapeutics is seeking shareholder approval to amend its certificate of incorporation, aiming to replace existing supermajority voting requirements with majority-of-outstanding standards and permit stockholder action by written consent. The Board unanimously recommends a", "url": "https://www.stocktitan.net/sec-filings/TPST/pre-14a-tempest-therapeutics-inc-preliminary-proxy-statement-40c3de5ad0b5.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:44:23", "published_display": "07 Jul 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tempest Therapeutics, Inc. \u2013 NASDAQ:TPST", "summary": "The article focuses on the enterprise value to revenue forward metric for Tempest Therapeutics, Inc. (NASDAQ: TPST). It appears to be a financial data point presented within a TradingView context, potentially indicating an analysis or overview of the company's valuation. However,", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:10:50", "published_display": "04 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Names Nicholas Maestas CFO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-names-nicholas-maestas-125504442.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:55:04+00:00", "published_display": "29 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TPST Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Tempest Therapeutics, Inc. (TPST), including analyst price targets and future predictions. It details the company's current stock performance, market capitalization, earnings, and revenue, alongside responses to frequently asked questions abou", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T05:09:10", "published_display": "27 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Registers 2.43 Million Shares for Resale", "summary": "Tempest Therapeutics has registered 2.43 million shares for resale, as detailed in a recent SEC filing. This move allows existing shareholders, likely including certain investors or employees, to sell their shares on the open market. The registration does not indicate a new issua", "url": "https://www.moomoo.com/news/post/72126797/tempest-therapeutics-registers-2-43-million-shares-for-resale?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-27T00:09:10", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TPST: Selling Stockholders Plan to Offer 2.43 Million Shares", "summary": "Certain stockholders of Tempest Therapeutics Inc (TPST) plan to sell 2.43 million shares of common stock. The company itself will not participate in the sale or benefit from the proceeds. TPST, a small-cap biotechnology company with a market cap of $15.99 million, has a low GF Sc", "url": "https://www.gurufocus.com/news/8934705/tpst-selling-stockholders-plan-to-offer-243-million-shares", "source_name": "GuruFocus", "published_at": "2026-06-26T20:40:39", "published_display": "26 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares from warrants", "summary": "Tempest Therapeutics (NASDAQ: TPST) has registered up to 2.43 million shares of common stock for resale by selling stockholders, stemming from new and placement agent warrants. The company will not receive proceeds from these resales, but could gain approximately $4.23 million if", "url": "https://www.stocktitan.net/sec-filings/TPST/s-3-tempest-therapeutics-inc-shelf-registration-statement-cd969c4f007b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T19:40:39", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Tempest Therapeutics, Inc. \u2013 NASDAQ:TPST", "summary": "This page provides financial data, primarily the \"Price to earnings forward\" value, for Tempest Therapeutics, Inc. (NASDAQ: TPST). It indicates that the company's market is currently closed with no trades. The content is essentially a snapshot of a financial data point from Tradi", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:39:31", "published_display": "26 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tempest Therapeutics, Inc. \u2013 NASDAQ:TPST", "summary": "This page displays the \"Price to sales forward\" metric for Tempest Therapeutics, Inc. (NASDAQ: TPST) on TradingView. The content is primarily navigation and boilerplate information from the TradingView platform, with no specific financial data or analysis for TPST provided on thi", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:49", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tempest Therapeutics, Inc. \u2013 LS:A41556", "summary": "This article provides the \"Price to sales forward\" value for Tempest Therapeutics, Inc. (A41556) on TradingView. It indicates that the market is closed and no trades have occurred for this specific period, presenting the financial data as \"No trades.\" The brief content focuses so", "url": "https://www.tradingview.com/symbols/LS-A41556/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:39:31", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics, Inc. Actuals & Estimates (NASDAQ:TPST)", "summary": "This article provides an overview of Tempest Therapeutics, Inc. (NASDAQ:TPST) stock performance, financial actuals, and future estimates. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report. The piece also", "url": "https://www.tradingview.com/symbols/NASDAQ-TPST/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:49", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TPST PE Ratio & Valuation, Is TPST Overvalued", "summary": "This article analyzes the valuation of Tempest Therapeutics Inc (TPST), stating that it is currently in the \"Fair zone\" based on its forward P/S ratio compared to its five-year average. It details various financial metrics such as P/B ratio and Free Cash Flow yield, noting signif", "url": "https://intellectia.ai/en/stock/TPST/valuation", "source_name": "Intellectia AI", "published_at": "2026-06-24T12:39:25", "published_display": "24 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Tempest Therapeutics Inc For: 23 June By Investing.com", "summary": "This article reports on the filing of a Form 8K by Tempest Therapeutics Inc. on June 23, 2026. The brief notice from Investing.com indicates this financial filing is available for public consumption. It is a standard reporting for a company, signifying a significant event worthy ", "url": "https://ng.investing.com/news/stock-market-news/form-8k-tempest-therapeutics-inc-for-23-june-93CH-2569463", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T03:41:07", "published_display": "24 Jun 2026 03:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tempest Therapeutics Inc For: 23 June By Investing.com", "summary": "The article reports on a Form 4 filing for Tempest Therapeutics Inc. on June 23, 2026, as published by Investing.com. It is a brief news item indicating a regulatory disclosure for the company. The specific details of the Form 4 filing are not included in this snippet.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tempest-therapeutics-inc-for-23-june-93CH-2571002", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T22:10:00", "published_display": "23 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO-linked entity boosts Tempest (TPST) stake with stock and new warrants", "summary": "An entity linked to Tempest Therapeutics CEO, Factor Bioscience Inc., acquired 231,482 shares of common stock and warrants to purchase an additional 462,964 shares at a combined price of $2.16 per share plus a warrant. The CEO, Matthew Angel, controls Factor Bioscience and thus i", "url": "https://www.stocktitan.net/sec-filings/TPST/form-4-tempest-therapeutics-inc-insider-trading-activity-67904dbd08cd.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:25", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (Nasdaq:TPST) - Stock Analysis", "summary": "Tempest Therapeutics (TPST) is a clinical-stage biotechnology company focused on developing therapies for cancer, with a market capitalization of US$18.6 million. The company faces significant risks including shareholder dilution, negative earnings forecasts, low revenue, and Nas", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tpst/tempest-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-23T16:10:44", "published_display": "23 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (NASDAQ: TPST) holders approve warrant share issuances", "summary": "Tempest Therapeutics (NASDAQ: TPST) stockholders approved two proposals at their 2026 Special Meeting, authorizing the potential issuance of common stock related to previously issued warrants. This includes shares for Series A, Series B, and Common Warrants, formalizing prior fin", "url": "https://www.stocktitan.net/sec-filings/TPST/8-k-tempest-therapeutics-inc-reports-material-event-882932a13584.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:10:39", "published_display": "23 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics shareholders approve issuance of up to 4.2 million shares", "summary": "Tempest Therapeutics shareholders have approved the issuance of up to 4.2 million common shares related to outstanding warrants, following a special meeting. The biotech company, trading near its 52-week low, secured these approvals under Nasdaq Rule 5635 due to thresholds on out", "url": "https://m.investing.com/news/sec-filings/tempest-therapeutics-shareholders-approve-issuance-of-up-to-42-million-shares-93CH-4755001?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T10:10:39", "published_display": "23 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics, Inc. 8-K Filing \u2013 Special Meeting Results, Common Stock Issuance Approved, Company Details (June 2026) \u2013 Minichart", "summary": "Tempest Therapeutics, Inc. announced the results of its 2026 Special Meeting, where shareholders approved the issuance of over 4 million new common shares under Nasdaq Rule 5635. These approvals for Series A and B warrants, and inducement offer warrants, enable the company to rai", "url": "https://www.minichart.com.sg/2026/06/23/tempest-therapeutics-inc-8-k-filing-special-meeting-results-common-stock-issuance-approved-company-details-june-2026/", "source_name": "Minichart", "published_at": "2026-06-23T10:10:39", "published_display": "23 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Tempest Therapeutics Inc (TPST), outlining major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over recent quarters, and recent shareholder activity with specific change", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tpst/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T16:10:52", "published_display": "18 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Inc (TPST) Institutional Confidence", "summary": "This article from TradingKey provides an overview of institutional confidence in Tempest Therapeutics Inc (TPST). It details the shares held by various institutional shareholders, including Angel (Matthew), Lotus Capital Limited, and Versant Ventures, along with changes in their ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tpst/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T14:09:30", "published_display": "18 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Inc (TPST) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Tempest Therapeutics Inc (TPST). It states that no dividends have been distributed over the past five years and lists several merger-related stock splits with their corresponding dates and ratios. The company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tpst/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:05", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Tempest Therapeutics (TPST) receives 25,000 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQQUQ0M1Ztc1Z6ODJlTC1iY0Jhc1VJSE1GYV8tUXpEYU82RXF5dXR3UDBpWVZhNGoxbFY2ekF1XzJWT01panZLRDVTcWZReEtIazdhbXAtTVZZNWtGMXEwV0xtSTZSdkxvZWZKUzIyS3BMMXE1RkxsMnhoNjdhUXZoRGlRSy14VXJEeWJiWDJXQmxrQUl1aS1SQUl6QzAtU1ZrSC1sandNbVZ2RmFncHlaUFBMdGp4Q0tFdmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 3] Tempest Therapeutics, Inc. Initial Statement of Beneficial Ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOdzlyTXBUSkY0LWJQVnRqdlh2M2d4SUNxZ2o1czU2N19BSjBSOVBqRFhtbkw5UVkwQWt0NjFaOE9JdnFyV09QSzZmd2F3RnR5cmtZbkZmVGVZczlibmhiemdpaTZ3OTB0LXpfaVcxYlBWRjN6UzQ0dW10dXpINWt6M1NxcjNQeFMtVXpFVTg3VWNDVHZyb2Y5b3ZUVkxRYXBKd05jVTBNcEtlbTNNeEthMU5xeGtPc0dOVE56TWhONkM2UEhMcG9oSFMxTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics CFO Nicholas Maestas Resigns", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-therapeutics-cfo-nicholas-maestas-100531808.html", "source_name": "MT Newswires", "published_at": "2026-06-05T10:05:31+00:00", "published_display": "05 Jun 2026 10:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-therapeutics-appoints-drake-richey-203700033.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T20:37:00+00:00", "published_display": "04 Jun 2026 20:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest building CAR-T cancer drugs adds two seasoned directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWHJldjVSWjVFcnQwSXAzN2lnOEpYQWFCb095WmpCSWZtSTNxNzl1Z0loTGNONzhvWGtoTFBCeUZ3MGlYTXVEb0hQVy1oTG0yUXhEODg0SzBWWDdVcU8xa2J5anZHeXhtWmVCcU9QOEd1aTRSUEtMcE1Fa1RfdnB0Wk9KQ05hR05aVVFmT2w5Tl9sVFBiQ3l6XzRfQ1paRU1sN2FJRkwybmNTbHdfTC1HZG1UWFRaLU1UODBWMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOeXZ2NEpMME5rV0NDcE5lR0xadjI3NXdrak93M3FhZmpydTdfRnd4TUVpVWViN0xpMGc5WjlGZ2lCYThmMVZVVk1oNlVEQWF4a3JGaGI4dzQwSWVyaVhQVWg1Yk1FUDUwU05VamxaeEF5NUdVS1Z0cjgyVkFEdzdseVNITnZpa1VnM0VqTm1hOTlwNGZTRTNWODdhX2g2SG5mUDg1M01GdGVaTFF1OXVDby11cGpQLXcxaC1aWUJFLUhnLW4zVHBWUUg1VHlGbXljN2JfdGRoTE0zclFZV0NBU3lLNzBpYjctbW82ZXlVZkd5ZEhjQk1TUw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer-focused Tempest pursues $2M upfront, $4M potential in warrant deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNM1RxX0trSEh0WHR2ZlloQzNaaUw5Um9JSWpDU25QRkdMSHhJc2NXVU9EWWd4ZWpsdzFzSXVoa0VrZEdjTnFXVGZmYUoybGJZRjlDY0xuYk5wSjFCT2RXNWtrbWRLUXFQM3F4ZzFlOGZ4SG1MYVVLSUdmekpZQ1RXaVRLVjV3dXlfcUVEbnJZQmZQSVBfRXRESEpJZGlOVTRXNHZXT0JVa3R6eVhXbG5SckhMX2xVN3Rrb2xKRXY4cw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNeDkzd0k0NGY0c1V0bmxPSFBHbmhzOXJBOEE5YkJOY29IWk5ldFBUMGRjQmlHSV8xRHBMaGN3ZklnUlFVZEJPZzV0dENEVlY4WkNDNmpQSHd6UkpEVlRBSlBDRENPc1lqcnQteFVDOUVGdzVERER1dTE2bG1KeVRZUkl2aDVmSlJKMmItMkl3Y1REZHRiemh3Tm15U1BscVV1Uk5fV1FyZ1BhUjBPdTlZNGttdEdKLWFjR1dDaVVnbmNmWERYRWZjV05teWFMM1I3RXBQS19WQzdNRm95ZGlXdGl4NTc2NVJV?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Presents Clinical Update at ISCT 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-presents-clinical-isct-2026-110000573.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:00:00+00:00", "published_display": "06 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tempest-advance-dual-targeting-car-120000162.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T12:00:00+00:00", "published_display": "29 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxOYUM5TFJjVHBocEJKYTJLejJHZUtOX0ZrY0U1Q2xsbGpfcllUMlhmZnV3dlhvak92X0lNbGdEcGRFUnVNc3Q4R3Z6YkdUZjJQb1pQRnlpZXBUMFFaRjhyS1BEbzh5LVV5N1ZSWXR5dkdqVUxDZ0F6Y2hoaDAzMl9wYzlJdGtvTVo0X3Q1VGpRZEhaU010c3RGTTF5Z080bVROdWJDLTVWaE02SUJsRC02TFcyN2wyY2NXbl90UWZZU09nWld6RDIwY3NELXFQTWlKTEhVbms2VUtIeGxLYVNSdWxBOUtncmRjZzlqZG1wZ1VDTkFL?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After 6 of 6 complete responses, Tempest moves toward pivotal CAR-T study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQb0k3Y0t5WWhwR0ZVcjFyZWwzNlY1T3psdTFuSXU4UTJab2JLN21HOGdQY2ViVS1yZ3pwRFdZV1BsUDE5MHdIbjRhdmpSWXNYRmM4elAtYjE5WndCQ3k5NGh5YW4xS2ptTHc1OXNMQkNxSHR0T0xFRXJBa2ZKdWFTWUtVSXZMZkI0eWNkY3RhWllybWpSeHljMDVOb0lzdExMVXBUM1NjTVJpeWRTSUlTaTRITzJiX21saTB3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Tempest Therapeutics (TPST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9haXVWS3QtbnpQb29kMGZHWjNxSF9QYjdfVzkxaGtqaXRfcnNEZFJJSXRJckRwX05rWmlfbGdJbWRrdlhWRE52WkttUUozaS1oWWlNNGF4MEo0SGhVVU1jeG1qVzVYbUNFcm9vSg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Announces Up To $6 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPR1g0Ymc1XzB4bWNSbzJfcTVUZzBNQjcyemFQZVkxcUxWQnZiZGtxTnJhNGd5QlcwRzBYR3JUV0VEbDJCSW9RaXZGdjZReGpCVW1TX1BYV2w4MjFXazl0eHFkOFRFUkwxRFNoUDE2UFdISU1xdWg2RXE2Y1J5dmwzTl9DaHNJN0pJeFZIa0l1UWVFQmxSTjI4SThiUTZST0lyU2tMaDFLVDRZS2ZRb0Nfa3pFNHRQSnpkTDJXSVQ5TDZ5RF9CX19fQ0drTHdCOWw4Unc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOM2JOY1BUTDR5X2p5ckZScTQ5UHVEWGt4RkhBZE5RWm5sUERLdEJYX0pmT1ltZ1B5Vy1adWxhVzQ5SGxiUUtTNm90Q0gwRVpVdndmdGpXX3lUZDhsWHRJb3pRTXhNNmc2VXlNRUR0RHBoa1ExQW85WnVSOTEyWUtvbmZnenVoZFNHVkdSRXVDQ2UtTHZsaGwwTkF0VV9kMWFVV0JtcGxWSmNWOWtjY014Q2l5VUJHV1cwT1M4akkxTFE4M2xIcFU2bTN4dEExWDY3X2hnbEZZeE1zcjdaazBFR0lIYzgtOWtsTHRrVUNheVpic2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics stock plunges after all-stock acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNDhPN25jU0h1WnVtLS05T3pZN1ZPNnlwNVpJWUtKTGxyd2p6ejZiN3JHVGxHVGIzVXZwblN2UXFfZTZpaVhUWEZpUUtKLUNqNWdBYVNvU252V0RxRWVEMVctME5xaGNpUGY1aFNLSTFLT1ZZQ2ZwbHA4MUdwb0dhU2pQT253M1RIUTdWVC1wRjQ3U0F0SG1KRGJtaG0xQ09meGdkZ0pOOWVEekpaQ3gzTENrVW1PcENjUVJfQUw2OGM?oc=5", "source_name": "Investing.com", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (TPST) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9fdXBYdkRwc213LXQ5SmViSC1DM0pDck1CMWtDczNYRWNFSVZkZkk1MG5wNEFsdzhwSk5HbW52cnUteW05akxUNmowcWhFeUFiUlFV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T17:35:29+00:00", "published_display": "24 Apr 2025 17:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics (TPST) Stock Price, News & Analysis $TPST", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5hQktWYk1PYTQ2aXVJdDhBenY0MXhNaDlBLWcwa2VsOHlWdnRaMzFMLVRPMzU2b2NnbW9GcjNZQXk0dURTQzhZNkpyRFFtVWVrMWxLWHRJS1dkdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-29T14:38:08+00:00", "published_display": "29 Jun 2021 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 56, "sentiment_summary": {"positive": 6, "negative": 7, "neutral": 43, "score": 50, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.97, "latest_week": "2026-07-10", "one_week_move": -10.7, "four_week_move": -22.8, "twelve_week_move": -50.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.350935, "market_dynamics_buy_signal": false, "relative_strength": -82.940047, "fair_value_gap": -94.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 35.9073, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.7% over one week, -22.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "GlobeNewswire", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "Market source", "count": 5}, {"label": "TradingKey", "count": 3}, {"label": "Quiver Quantitative", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 17}, {"label": "Deals and strategy", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.7% over one week, -22.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com"}], "updated_at": "2026-07-16T17:59:10.553769+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}